UBS Maintains Neutral on IDEXX Laboratories, Lowers Price Target to $620

Benzinga Newsdesk www.benzinga.com Negative 83.8%

Neg 83.8% Neu 0% Pos 0%

UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and lowers the price target from $640 to $620.